U.S., Europe Drug Makers Miss M&A Prospects By Ignoring China Firms
This article was originally published in PharmAsia News
Executive Summary
Chinese drug makers have enough funds to expand their own portfolios and market them abroad, but face a negative bias by U.S. and European companies that lose a lot of profitable opportunities.